12/4
02:02 pm
mrus
Merus N.V. (MRUS): A Bull Case Theory [Yahoo! Finance]
Low
Report
Merus N.V. (MRUS): A Bull Case Theory [Yahoo! Finance]
11/17
07:10 am
mrus
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab [Yahoo! Finance]
Low
Report
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab [Yahoo! Finance]
10/31
10:07 am
mrus
Merus (NASDAQ:MRUS) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.
Low
Report
Merus (NASDAQ:MRUS) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.
10/25
12:09 pm
mrus
Merus (NASDAQ:MRUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Merus (NASDAQ:MRUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/24
10:00 am
mrus
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
Low
Report
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
10/23
12:43 pm
mrus
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
Low
Report
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
10/14
07:40 am
mrus
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
Low
Report
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
10/14
07:30 am
mrus
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Low
Report
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/13
12:07 pm
mrus
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
Neutral
Report
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
10/13
12:00 pm
mrus
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Low
Report
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/7
07:53 am
mrus
Merus (NASDAQ:MRUS) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Low
Report
Merus (NASDAQ:MRUS) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
10/6
06:01 am
mrus
Merus (NASDAQ:MRUS) was given a new $97.00 price target on by analysts at Leerink Partners.
Low
Report
Merus (NASDAQ:MRUS) was given a new $97.00 price target on by analysts at Leerink Partners.
10/2
05:10 pm
mrus
Merus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth Potential [Yahoo! Finance]
Low
Report
Merus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth Potential [Yahoo! Finance]
10/1
05:47 am
mrus
Merus (NASDAQ:MRUS) was downgraded by analysts at Lifesci Capital from a "strong-buy" rating to a "hold" rating.
Neutral
Report
Merus (NASDAQ:MRUS) was downgraded by analysts at Lifesci Capital from a "strong-buy" rating to a "hold" rating.
10/1
05:47 am
mrus
Merus (NASDAQ:MRUS) was downgraded by analysts at Barclays PLC from a "strong-buy" rating to a "hold" rating.
Neutral
Report
Merus (NASDAQ:MRUS) was downgraded by analysts at Barclays PLC from a "strong-buy" rating to a "hold" rating.
10/1
05:47 am
mrus
Merus (NASDAQ:MRUS) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
Neutral
Report
Merus (NASDAQ:MRUS) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
9/30
09:59 pm
mrus
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
Neutral
Report
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
9/30
08:04 pm
mrus
Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium [Yahoo! Finance]
Low
Report
Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium [Yahoo! Finance]
9/30
05:30 pm
mrus
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS)
Low
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS)
9/30
10:39 am
mrus
Merus (NASDAQ:MRUS) had its "neutral" rating reaffirmed by analysts at Guggenheim. They now have a $97.00 price target on the stock, down previously from $109.00.
Low
Report
Merus (NASDAQ:MRUS) had its "neutral" rating reaffirmed by analysts at Guggenheim. They now have a $97.00 price target on the stock, down previously from $109.00.
9/30
08:05 am
mrus
Merus (NASDAQ:MRUS) had its "market perform" rating reaffirmed by analysts at Lifesci Capital. They now have a $97.00 price target on the stock.
Low
Report
Merus (NASDAQ:MRUS) had its "market perform" rating reaffirmed by analysts at Lifesci Capital. They now have a $97.00 price target on the stock.
9/30
07:03 am
mrus
Merus (NASDAQ:MRUS) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating.
Low
Report
Merus (NASDAQ:MRUS) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating.
9/30
07:03 am
mrus
Merus (NASDAQ:MRUS) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
Low
Report
Merus (NASDAQ:MRUS) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
9/30
07:01 am
mrus
Merus (NASDAQ:MRUS) was given a new $97.00 price target on by analysts at Barclays PLC.
Low
Report
Merus (NASDAQ:MRUS) was given a new $97.00 price target on by analysts at Barclays PLC.
9/30
06:23 am
mrus
Merus (NASDAQ:MRUS) was downgraded by analysts at Wells Fargo & Company from a "strong-buy" rating to a "hold" rating.
Low
Report
Merus (NASDAQ:MRUS) was downgraded by analysts at Wells Fargo & Company from a "strong-buy" rating to a "hold" rating.